News

Merck has updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the company’s investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its efforts to

Pluristem has started enrolling patients in the US for a phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the company’s lead product candidate for

The FDA has removed the clinical hold for Dynavax Technologies’ (Dynavax) Heplisav Investigational New Drug (IND) application in individuals with chronic kidney disease. HEPLISAV is a phase 3

Centocor Ortho Biotech has received a Complete Response Letter from the FDA regarding the New Drug Application (NDA) for trabectedin, when administered in combination with DOXIL (doxorubicin HCI

Ascenta Therapeutics has revealed that (following the approval by the FDA for AT-406, an orally-active, small molecule, multi-IAP antagonist) it will initiate a phase 1 clinical trial in

Scarab Genomics has entered into a license agreement with NeoClone to market and distribute their antibodies against Shiga toxin. This toxin is secreted by E. coli bacteria, which

Quintiles has reported a strategic alliance agreement with the University of Pretoria as part of its Prime Site program, an initiative to accelerate the development of new and

Halozyme has reported first patient dosing in a phase 1 pharmacokinetic clinical trial using Enhanze Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.